Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Receives $3.2 Billion Privatization Offer

publication date: Apr 30, 2015
WuXi PharmaTech, China's largest CRO/CMO, announced a surprise privatization offer of $46 per ADS from Dr. Ge Li, the company's founder, chairman and CEO, and Ally Bridge Group Capital Partners. Before the offer, WuXi closed at $39.50. If the offer is completed, WuXi would be the largest privatization transaction in China's life science sector. Shortly after the New York opening, the company's stock is trading at $44.41, giving the company a market capitalization of over $3.1 billion and a trailing price-earnings ratio of 26. More details....

Stock Symbol: (NYSE:WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital